CRISPR-Cas gene editing technologies offer revolutionary potential for treating genetic forms of atypical parkinsonism. While clinical application remains years away, understanding these approaches helps patients and families make informed decisions about research participation and future therapeutic options.
CRISPR-Cas gene editing technologies offer revolutionary potential for treating genetic forms of atypical parkinsonism. While clinical application remains years away, understanding these approaches helps patients and families make informed decisions about research participation and future therapeutic options.
Overview
Mermaid diagram (expand to render)
Gene editing uses molecular tools to directly modify DNA sequences, potentially correcting disease-causing mutations or modulating gene expression. For CBS and PSP, which involve tau pathology (4R-tauopathy), several genetic targets are relevant, including MAPT (tau gene), GBA (glucocerebrosidase), and GRN (progranulin)[@guo2024].
CRISPR Technologies
CRISPR-Cas9
The original CRISPR system uses Cas9 endonuclease to create double-strand breaks at targeted genomic locations.
Components:
Guide RNA (gRNA): Directs Cas9 to specific genomic sequence
Cas9 protein: Creates double-strand break
Repair template: Provides corrected sequence for homology-directed repair
Limitations:
Double-strand breaks can cause unintended edits
Requires break and repair process
Large size of Cas9 limits delivery options
Base Editing
Base editing allows precise single-nucleotide changes without double-strand breaks.
Types:
Cytosine base editors (CBE): Convert C→T
Adenine base editors (ABE): Convert A→G
Glycosylase base editors: Expanded targeting
Advantages:
No double-strand breaks
Precise single-nucleotide changes
Reduced off-target effects
Example Applications:
Correcting MAPT P301L mutation
Modifying GBA variants
Creating protective APOE variants
Prime Editing
Prime editing uses Cas9 fused to reverse transcriptase for precise insertions, deletions, and substitutions.
[Doudna JA, Charpentier E, The new frontier of genome engineering with CRISPR-Cas9 (2014)](https://pubmed.ncbi.nlm.nih.gov/25430774/)
[Guo Q, et al, CRISPR-Cas9 for tauopathy: Targeting MAPT mutations (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)
Pathway Diagram
The following diagram shows the key molecular relationships involving CRISPR Gene Correction Approaches for CBS/PSP discovered through SciDEX knowledge graph analysis: